Aducanumab update: detailed data reported on ‘resurrected’ Alzheimer’s drug

Written by Sharon Salt, Editor

In March 2019, a decision to discontinue the global Phase III trials of aducanumab for Alzheimer’s disease (AD) shook the field. Little to no information was provided about why the compound failed at the time – did it not lower plaque burden? Was there too much measurement variability? The answer remained uncertain. However, in a big turn of events, Biogen (MA, USA) and Eisai (Tokyo, Japan) decided in October 2019 that they were going to pursue regulatory approval for the drug after analysis with a larger data set indicated that there was a reduction in clinical decline compared with the...

To view this content, please register now for access

It's completely free